Molina Healthcare Inc. (MOH)

Molina Healthcare's stock is trading near the upper part of its 52-week range, but the business is under pressure: revenue shrank 4.84% in the latest quarter year on year, and return on equity is negative. Analysts are mostly neutral. Three of 19 rate the stock buy, 15 hold and one sells, and the median 12-month target of $222.00 sits 6.1% above the price. The stock rose 1.41% in the last session but fell 7.58% over the past week, and it trades 14.55% below its 52-week high of $244.89.

Molina's revenue fell 4.84% in the latest quarter compared with the same quarter a year earlier. This is the factor that holds the CleaRank score down most. A managed care company that loses top-line momentum while the sector expands has to show that margin or membership is improving to justify its position, and that improvement is not yet visible in the latest results. Net profit margin is -0.1%, operating margin is 0.64%, and return on equity is -1.15%, against a sector median of 7.3%.

The stock is up 45.80% over the past year and 9.00% over six months, and it sits 12.77% above its 200-day SMA and 3.43% above its 50-day SMA. The 50-day SMA is 9.02% above the 200-day SMA, which shows the longer trend has been rising. The price is not yet back at its high, however. It is 14.55% below the 52-week high of $244.89, and it fell 7.58% over the past week. Over one month the stock rose 2.39%. The gap between that strong one-year return and the shrinking revenue is the central tension for investors to weigh.

The price-to-sales ratio is 0.26, against a sector median of 3.4, which puts the stock 92.4% below the median on that measure. Investors are paying very little for each dollar of revenue, but that low multiple reflects the thin profit margins. Insiders sold $4.1M of stock in six sales over the last 18 months and bought $1.7M in two open-market purchases. Insider sales are often planned in advance or made to cover tax on vesting shares, so they are a weaker signal than the open-market purchases.

Analysts rate the stock Hold on balance. Three of 19 rate it buy, 15 hold and one sell. On October 23, 2026, UBS, Morgan Stanley, RBC Capital and Barclays each kept their existing ratings, with Barclays keeping an Underweight rating. JP Morgan kept its Neutral rating on October 27, 2026, and Wells Fargo kept its Equal-Weight rating on July 28, 2026. None of the recent analyst actions was a rating change, so the consensus has held steady. The median 12-month target is $222.00, 6.1% above the price.

The base case is that MOH holds its position above its 50-day and 200-day moving averages ($202.30 and $185.56) while the market waits for evidence that the top line can return to growth. For that to happen, revenue has to stop shrinking, and margins have to move from near break-even toward a level that supports the balance sheet. If revenue growth returns and profitability improves, the stock has room to test the 52-week high of $244.89, and the median analyst target of $222.00 would then look more reachable. If revenue keeps falling or the price loses the 20-day EMA and the 50-day SMA, the lowest analyst target of $163.00 becomes the reference point for a more cautious view. Analysts' targets range from $163.00 to $266.00, so their views are spread widely.

Support sits first at the 20-day EMA of $207.48, which is just below the price of $209.25. Below it, the 50-day SMA at $202.30 is the next level a decline would meet, and the 200-day SMA at $185.56 is the third. The 52-week low of $121.06 is far below and marks the bottom of the stock's one-year range. On the upside, the 52-week high of $244.89 is the first level above the price that a rise would meet.